EichorEICHOR
Condition: Myelofibrosis Transformation In Essential Thrombocythemia Synced from ClinicalTrials.gov · August 06, 2026

Recruiting studies: Myelofibrosis Transformation In Essential Thrombocythemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Phase 3 · 30 location(s) · Novartis Pharmaceuticals · NCT07357727A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
Phase N/A · 3 location(s) · Bristol-Myers Squibb · NCT06073847Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Phase 1/Phase 2 · 28 location(s) · Disc Medicine, Inc · NCT05320198MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal
Phase 1/Phase 2 · 19 location(s) · Telios Pharma, Inc. · NCT05280509Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06770842Asian Myeloproliferative Neoplasm (MPN) Registry
Phase N/A · 1 location(s) · The University of Hong Kong · NCT05882773Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2 · 33 location(s) · GlaxoSmithKline · NCT06517875A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Phase 3 · 21 location(s) · Merck Sharp & Dohme LLC · NCT06351631A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Phase 1 · 8 location(s) · Prelude Therapeutics · NCT07469891Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Phase 1/Phase 2 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT06773195Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07340138Research Platform Myelofibrosis and Anemia
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06976918Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Phase 2 · 9 location(s) · Icahn School of Medicine at Mount Sinai · NCT05835466Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Resp
Phase 3 · 215 location(s) · Kartos Therapeutics, Inc. · NCT06479135A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Phase 1 · 21 location(s) · Ajax Therapeutics, Inc. · NCT06343805Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 · 1 location(s) · Fox Chase Cancer Center · NCT06218628Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibr
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06327100Therapeutic RSK1 Targeting in Myelofibrosis
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT07379125
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.